{"id":46883,"date":"2022-08-03T15:02:13","date_gmt":"2022-08-03T13:02:13","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/propanc-biopharma-establishes-joint-research-collaboration-agreement-with-the-universities-of-jaen-and-granada\/"},"modified":"2022-08-03T15:02:13","modified_gmt":"2022-08-03T13:02:13","slug":"propanc-biopharma-establishes-joint-research-collaboration-agreement-with-the-universities-of-jaen-and-granada","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/propanc-biopharma-establishes-joint-research-collaboration-agreement-with-the-universities-of-jaen-and-granada\/","title":{"rendered":"Propanc Biopharma Establishes Joint Research Collaboration Agreement with the Universities of Ja\u00e9n and Granada"},"content":{"rendered":"
\n

\nResearch Evaluates Effects of Against the Tumor Microenvironment<\/i>\n<\/p>\n

MELBOURNE, Australia–(BUSINESS WIRE)–Propanc Biopharma, Inc.<\/b><\/a> (OTCQB: PPCB) (\u201cPropanc\u201d or the \u201cCompany\u201d), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that a Joint Research Collaboration Agreement has been established with the Universities of Ja\u00e9n and Granada, Spain. Since late 2020, Mrs. Bel\u00e9n Toledo Cutillas MSc, has been investigating an important experimental thesis on the effects of proenzyme therapy and the impact on the tumor microenvironment, which is key to the development, invasion, metastatic spread and recurrence of solid tumors. The work is being conducted at the laboratory of Professor Macarena Per\u00e1n PhD, who is the lead researcher on the project and is the second Joint Research Collaboration Agreement currently in progress with the two Spanish Universities.\n<\/p>\n

<\/a><\/p>\n

\nTo date, encouraging results demonstrates that proenzymes have specific effects on tumor cells and CSCs, but also other tumor elements in the tumor microenvironment. However, the most significant conclusion is that proenzymes cause a reversal of the malignant phenotype (observable characteristics) towards a normal, or benign state. This process of reversing the tumor phenotype, called differentiation, is how proenzymes exert anti-tumor, anti-cancer and anti-metastatic effects. Therefore, proenzyme treatment may be considered differentiation therapy, which exerts these effects on malignant cells, but leaves healthy cells alone. To achieve these results, Mrs. Cutillas used integrated 3-dimensional bio-impressions of tumor cells from patients with advanced solid tumors, developed at the Centre for Biomedical Research, University of Granada, led by Professor Juan Marchal MD.\n<\/p>\n

\nAlong with lead researcher, Professor Per\u00e1n, and Mrs. Cutillas, additional research team members from the University of Ja\u00e9n are assisting on the project, as well as Professor Marchal and Dr Maria Angel Garcia, from the University of Granada. Propanc will own any intellectual property developed during the research, and publishing rights, in exchange for any net future royalties from intellectual property rights.\n<\/p>\n

\nDr Julian Kenyon, Md, MB, ChB, Propanc\u2019s Chief Scientific Officer said, \u201cEvaluating the effects of proenzyme therapy in the tumor microenvironment is of scientific interest, as it demonstrates whether proenzymes penetrate into this target area and exert its effects. At the same time, it confirms the selectivity of the drug on solid tumors, by targeting cancer cells and leaving healthy cells alone. The clinical implications are also potentially significant, which may result in novel discoveries and lead to exciting new ways to treat cancer patients suffering from solid tumors without the toxicity normally associated with standard treatment regimens.\u201d\n<\/p>\n

\n\u201cContinuing to expand our research efforts in the use of proenzymes and cancer leading to the identification of further discoveries can provide additional patentable subject matter and expand our intellectual property portfolio, which covers the invention relating to our lead product candidate, PRP. I look forward to working closely with Professor Per\u00e1n and her team on this exciting project,\u201d said Mr. James Nathanielsz, Propanc\u2019s Chief Executive Officer.\n<\/p>\n

\nPRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells. Examples include kidney, ovarian, breast, brain, prostate, colorectal, lung, liver, uterine and skin cancers.\n<\/p>\n

\nAbout Propanc Biopharma, Inc.<\/b>\n<\/p>\n

\nPropanc Biopharma, Inc. (the \u201cCompany\u201d) is developing a novel approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells in patients suffering from pancreatic, ovarian and colorectal cancers. For more information, please visit www.propanc.com<\/a>.\n<\/p>\n

\nThe Company\u2019s novel proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas. These pancreatic enzymes could represent the body\u2019s primary defense against cancer.\n<\/p>\n

\nTo view the Company\u2019s \u201cMechanism of Action\u201d video on its anti-cancer lead product candidate, PRP, please click on the following link: http:\/\/www.propanc.com\/news-media\/video<\/a>\n<\/p>\n

\nForward-Looking Statements<\/b>\n<\/p>\n

\nAll statements other than statements of historical facts contained in this press release are \u201cforward-looking statements,\u201d which may often, but not always, be identified by the use of such words as \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cwill likely result,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cestimate,\u201d \u201cplan,\u201d \u201cproject,\u201d \u201cforecast,\u201d \u201cintend,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cseek,\u201d \u201ccontinue,\u201d \u201ctarget\u201d or the negative of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements. These factors include uncertainties as to the Company\u2019s ability to continue as a going concern absent new debt or equity financings; the Company\u2019s current reliance on substantial debt financing that it is unable to repay in cash; the Company\u2019s ability to successfully remediate material weaknesses in its internal controls; the Company\u2019s ability to reach research and development milestones as planned and within proposed budgets; the Company\u2019s ability to control costs; the Company\u2019s ability to obtain adequate new financing on reasonable terms; the Company\u2019s ability to successfully initiate and complete clinical trials and its ability to successful develop PRP, its lead product candidate; the Company\u2019s ability to obtain and maintain patent protection; the Company\u2019s ability to recruit employees and directors with accounting and finance expertise; the Company\u2019s dependence on third parties for services; the Company\u2019s dependence on key executives; the impact of government regulations, including FDA regulations; the impact of any future litigation; the availability of capital; changes in economic conditions, competition; and other risks, including, but not limited to, those described in the Company\u2019s periodic reports that are filed with the Securities and Exchange Commission and available on its website at http:\/\/www.sec.gov<\/a>. These forward-looking statements speak only as of the date hereof and the Company disclaims any obligations to update these statements except as may be required by law.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor Relations and Media:<\/b>
Mr. James Nathanielsz
\n
Propanc Biopharma, Inc.
\n
irteam@propanc.com<\/a>
+61-3-9882-0780\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Research Evaluates Effects of Against the Tumor Microenvironment MELBOURNE, Australia–(BUSINESS WIRE)–Propanc Biopharma, Inc. (OTCQB: PPCB) (\u201cPropanc\u201d or the \u201cCompany\u201d), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that a Joint Research Collaboration Agreement has been established with the Universities of Ja\u00e9n and Granada, Spain. Since late … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46883","6":"format-standard","7":"category-industry"},"yoast_head":"\nPropanc Biopharma Establishes Joint Research Collaboration Agreement with the Universities of Ja\u00e9n and Granada - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/propanc-biopharma-establishes-joint-research-collaboration-agreement-with-the-universities-of-jaen-and-granada\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Propanc Biopharma Establishes Joint Research Collaboration Agreement with the Universities of Ja\u00e9n and Granada - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Research Evaluates Effects of Against the Tumor Microenvironment MELBOURNE, Australia–(BUSINESS WIRE)–Propanc Biopharma, Inc. (OTCQB: PPCB) (\u201cPropanc\u201d or the \u201cCompany\u201d), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that a Joint Research Collaboration Agreement has been established with the Universities of Ja\u00e9n and Granada, Spain. Since late ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/propanc-biopharma-establishes-joint-research-collaboration-agreement-with-the-universities-of-jaen-and-granada\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-03T13:02:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220803005047\/en\/808594\/21\/propanc-logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/propanc-biopharma-establishes-joint-research-collaboration-agreement-with-the-universities-of-jaen-and-granada\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/propanc-biopharma-establishes-joint-research-collaboration-agreement-with-the-universities-of-jaen-and-granada\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Propanc Biopharma Establishes Joint Research Collaboration Agreement with the Universities of Ja\u00e9n and Granada\",\"datePublished\":\"2022-08-03T13:02:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/propanc-biopharma-establishes-joint-research-collaboration-agreement-with-the-universities-of-jaen-and-granada\\\/\"},\"wordCount\":1003,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/propanc-biopharma-establishes-joint-research-collaboration-agreement-with-the-universities-of-jaen-and-granada\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220803005047\\\/en\\\/808594\\\/21\\\/propanc-logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/propanc-biopharma-establishes-joint-research-collaboration-agreement-with-the-universities-of-jaen-and-granada\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/propanc-biopharma-establishes-joint-research-collaboration-agreement-with-the-universities-of-jaen-and-granada\\\/\",\"name\":\"Propanc Biopharma Establishes Joint Research Collaboration Agreement with the Universities of Ja\u00e9n and Granada - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/propanc-biopharma-establishes-joint-research-collaboration-agreement-with-the-universities-of-jaen-and-granada\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/propanc-biopharma-establishes-joint-research-collaboration-agreement-with-the-universities-of-jaen-and-granada\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220803005047\\\/en\\\/808594\\\/21\\\/propanc-logo.jpg\",\"datePublished\":\"2022-08-03T13:02:13+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/propanc-biopharma-establishes-joint-research-collaboration-agreement-with-the-universities-of-jaen-and-granada\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/propanc-biopharma-establishes-joint-research-collaboration-agreement-with-the-universities-of-jaen-and-granada\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/propanc-biopharma-establishes-joint-research-collaboration-agreement-with-the-universities-of-jaen-and-granada\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220803005047\\\/en\\\/808594\\\/21\\\/propanc-logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220803005047\\\/en\\\/808594\\\/21\\\/propanc-logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/propanc-biopharma-establishes-joint-research-collaboration-agreement-with-the-universities-of-jaen-and-granada\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Propanc Biopharma Establishes Joint Research Collaboration Agreement with the Universities of Ja\u00e9n and Granada\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Propanc Biopharma Establishes Joint Research Collaboration Agreement with the Universities of Ja\u00e9n and Granada - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/propanc-biopharma-establishes-joint-research-collaboration-agreement-with-the-universities-of-jaen-and-granada\/","og_locale":"en_US","og_type":"article","og_title":"Propanc Biopharma Establishes Joint Research Collaboration Agreement with the Universities of Ja\u00e9n and Granada - Pharma Trend","og_description":"Research Evaluates Effects of Against the Tumor Microenvironment MELBOURNE, Australia–(BUSINESS WIRE)–Propanc Biopharma, Inc. (OTCQB: PPCB) (\u201cPropanc\u201d or the \u201cCompany\u201d), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that a Joint Research Collaboration Agreement has been established with the Universities of Ja\u00e9n and Granada, Spain. Since late ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/propanc-biopharma-establishes-joint-research-collaboration-agreement-with-the-universities-of-jaen-and-granada\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-03T13:02:13+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220803005047\/en\/808594\/21\/propanc-logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/propanc-biopharma-establishes-joint-research-collaboration-agreement-with-the-universities-of-jaen-and-granada\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/propanc-biopharma-establishes-joint-research-collaboration-agreement-with-the-universities-of-jaen-and-granada\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Propanc Biopharma Establishes Joint Research Collaboration Agreement with the Universities of Ja\u00e9n and Granada","datePublished":"2022-08-03T13:02:13+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/propanc-biopharma-establishes-joint-research-collaboration-agreement-with-the-universities-of-jaen-and-granada\/"},"wordCount":1003,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/propanc-biopharma-establishes-joint-research-collaboration-agreement-with-the-universities-of-jaen-and-granada\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220803005047\/en\/808594\/21\/propanc-logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/propanc-biopharma-establishes-joint-research-collaboration-agreement-with-the-universities-of-jaen-and-granada\/","url":"https:\/\/pharma-trend.com\/en\/propanc-biopharma-establishes-joint-research-collaboration-agreement-with-the-universities-of-jaen-and-granada\/","name":"Propanc Biopharma Establishes Joint Research Collaboration Agreement with the Universities of Ja\u00e9n and Granada - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/propanc-biopharma-establishes-joint-research-collaboration-agreement-with-the-universities-of-jaen-and-granada\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/propanc-biopharma-establishes-joint-research-collaboration-agreement-with-the-universities-of-jaen-and-granada\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220803005047\/en\/808594\/21\/propanc-logo.jpg","datePublished":"2022-08-03T13:02:13+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/propanc-biopharma-establishes-joint-research-collaboration-agreement-with-the-universities-of-jaen-and-granada\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/propanc-biopharma-establishes-joint-research-collaboration-agreement-with-the-universities-of-jaen-and-granada\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/propanc-biopharma-establishes-joint-research-collaboration-agreement-with-the-universities-of-jaen-and-granada\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220803005047\/en\/808594\/21\/propanc-logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220803005047\/en\/808594\/21\/propanc-logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/propanc-biopharma-establishes-joint-research-collaboration-agreement-with-the-universities-of-jaen-and-granada\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Propanc Biopharma Establishes Joint Research Collaboration Agreement with the Universities of Ja\u00e9n and Granada"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46883","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46883"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46883\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46883"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46883"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46883"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}